Arcus Biosciences (RCUS) Stock Price, News & Analysis

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RCUS shares.
View RCUS analyst ratings or view top-rated stocks.

8 equities research analysts have issued 1 year price objectives for Arcus Biosciences' stock. Their RCUS share price targets range from $23.00 to $70.00. On average, they anticipate the company's share price to reach $41.25 in the next year. This suggests a possible upside of 178.0% from the stock's current price.
View analysts price targets for RCUS or view top-rated stocks among Wall Street analysts.

Arcus Biosciences' stock was trading at $19.10 at the beginning of the year. Since then, RCUS shares have decreased by 22.3% and is now trading at $14.84.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RCUS earnings forecast.

Arcus Biosciences, Inc. (NYSE:RCUS) announced its quarterly earnings data on Wednesday, February, 21st. The company reported ($1.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.01. The firm had revenue of $31 million for the quarter, compared to analysts' expectations of $28.30 million. Arcus Biosciences had a negative trailing twelve-month return on equity of 57.17% and a negative net margin of 262.39%. The company's revenue for the quarter was down 8.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.93) EPS.

ETFs with the largest weight of Arcus Biosciences (NYSE:RCUS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO).Invesco S&P SmallCap Health Care ETF (PSCH).

4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD).

Arcus Biosciences (RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

Arcus Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.01%), Diversified Trust Co (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Alexander Azoy, Carolyn C Tang, Carolyn C Tang, Gilead Sciences, Inc, Jennifer Jarrett, Juan C Jaen, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends.

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.